Biotech Daily Home

Biotech Daily covers the major announcements from more than 130 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A1080 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !

Rhythm Bio $9m IPO For Bowel Cancer Blood Test 

Telix $50m IPO Up 25% For Molecular Targeted Cancer Radiation 

Living Cell Tumbles 89% On NTCell Parkinson's Results

Biotech Daily 12th Birthday Editorial

Dr Boreham's Crucible - Nanosonics

Biotech Daily Editorial - Selective Briefings 

Biotech Revenue Up 194% In 8 Years To $1.4b

4-Year Data Backs Prota, MCRI Peanut Immunotherapy

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Novartis Buys Spinifex For $916m



October BDI-40 Up 7%, ASX Up 4%
Big Caps Up 6%, NBI Down 6%

Neuren Up 62%, Benitec 41%, Cyclopharm 33%
Cellmid Down 15%, Avita 14%

Nov 1, 2017

The Spring growth continues for the biotechnology sector – and records are tumbling.
Following September’s 4.2 percent Biotech Daily Top 40 Index (BDI-40) increase, October provided a further 6.9 percent boost, compared to the ASX200 up 4.0 percent for the month (see charts below).
Twenty-one companies of the BDI-40 (which does not include Cochlear, CSL and Resmed) were up, 17 fell and two were unchanged.
Significantly, 13 companies were up by more than 10 percent, of which five climbed more than 20 percent, with only three falling by more than 10 percent and only one of those, Compumedics, among the BDI-20.
The Old Guard led the charge, with Neuren recovering 62.1 percent to $248 million, its best since March 2015, followed by Benitec up 41.4 percent from a low base to $41 million.
Cyclopharm recovered 33.3 percent to $68 million, followed by Polynovo (30.1%), Medical Developments (22.0%), Oncosil (17.9%), Prana (16.7%), Nanosonics (15.0%), Pro Medicus (13.4%) and Dimerix (13.3%).
But the stand-outs were Cochlear breaking through the $10 billion mark, along with Nanosonics adding $117 million to its market cap to $898 million leading Sirtex at $788 million and Pro Medicus at $692 million, with Mesoblast easing 2.6 percent to $628 million.
Starpharma re-joined the $500 million club (which it touched in May 2012) up a further $37 million or 7.9 percent to $508 million. Well done, Dr Jackie Fairley!
The falls or more than 10 percent were limited to Cellmid down 14.8 percent to $23 million, Avita down 14.3 percent to $36 million and Compumedics retreating 13.8 percent to $56 million.
All three Big Caps of Cochlear, CSL and Resmed hit record highs at the end of October, up a collective 5.7 percent in October (and 37.7 percent for the 12 months to October 31), with Resmed up 11.3 percent to $15,407 million, Cochlear up 10.5 percent to $10,124 million and CSL up 3.7 percent to $62,879 million.
Outside the BDI-40, the recently listed Cann Group was up 46.7 percent to $132 million with Bioxyne, Epat, Imugene and all showing signs of progress.
In the US, Aviragen (Biota) was taking it last breaths, down 8.8 percent to $31 million, Protagonist fell 13.4 percent to $330 million and Redhill lost 15.6 percent to $200 million.
The Nasdaq Biotechnology index (NBI) fell 5.8 percent in October but was up 22.6 percent for the 12 months to October 31, 2017, compared to the ASX200 up 11.1 percent for the year and the BDI-40 down 11.9 percent.


BDI-40 v S&P ASX200 Jun 30, 2006 to Oct 31, 2017 
BDI-40 v S&P ASX200 Oct 31, 2016 to Oct 31, 2017 
Big Caps (Cochlear, CSL, Resmed) Year To Oct 31, 2017


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Oct 31, 2017


* Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Mesoblast, Nanosonics, Optiscan
   and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: